Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.
Rahman, Rifaquat , Trippa, Lorenzo , Fell, Geoffrey, Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Schiff, David , Welch, Mary , Reardon, David A. , Wen, Patrick Y. , Ahluwalia, Manmeet S , Fell, Geoffrey G. , Arrillaga‐Romany, Isabel , Touat, Mehdi , Drappatz, Jan , Galanis, Evanthia , Colman, Howard , Nabors, Burt , Meredith, David M. , Chiocca, E Antonio , Ligon, Keith L , Alexander, Brian M. , Wen, Patrick Yung

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 2006-2006

10.1200/jco.2021.39.15_suppl.2006 Get It

2006 Background: Adaptive randomization adjusts enrollment rates based upon early trial results, which can allow for decreased enrollment for therapies less likely to meet the primary endpoint of a trial. CC-115, a CNS-penetrant, oral inhibitor of mammalian target of rapamycin kinase (mTOR) and deoxyribonucleic acid-dependent protein kinase (DNA-PK), was evaluated in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial. As CC-115 was discontinued due to concerns about toxicity and unfavorable risk-to-benefit ratio, we sought to investigate the impact of adaptive randomization in its testing. Methods: In INSIGhT, adults with newly diagnosed MGMT-unmethylated glioblastoma and available genomic data are adaptively randomized to an experimental arm or the control arm of standard radiotherapy with concurrent and adjuvant temozolomide. Patients randomized to CC-115 received it (10mg po BID) with radiotherapy and as adjuvant monotherapy, and a safety lead-in 3+3 design was used for this arm. By simulating the INSIGhT trial with standard uniform randomization, we estimated the reduction of enrollment rate and sample size of the CC-115 arm that was attributable to adaptive randomization. Results: Twelve patients were randomized to CC-115; 58% (n = 7) patients had possible treatment-related CTCAE grade > 3 toxicity. Compared to the control arm, there was no significant difference in progression-free survival (PFS, HR 0.66, 95% CI 0.32-1.36, p = 0.3) or overall survival (OS, HR 0.93, 95% CI 0.43-2.03, p = 0.8). Based on early PFS results, randomization probability to CC-115 decreased from 25% to 16%. At the time of the CC-115 arm closure, 14% of enrolled INSIGhT patients had been randomized to this arm. Compared to average expected enrollment by standard randomization, the use of adaptive randomization decreased the number of patients randomized to CC-115 by 50% (12 patients vs. 18 patients [95% CI 11-25 patients]). Conclusions: The INSIGhT trial, designed with adaptive randomization, facilitated more efficient testing of CC-115 and decreased the number of patients allocated to the CC-115 arm relative to a standard randomization design. Clinical trial information: NCT02977780.
Nodule net: A prospective safety net program to reduce loss to follow-up and increase early detection of lung cancer.
Jani, Chinmay , Rupal, Arashdeep , Tewari, Arti , Walker, Alexander , Casasola, M , Khoory, Joseph, Koster, Megan , Thomson, Carey C. , Singh, Harpreet , Ranker, Lynsie R

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 1564-1564

10.1200/jco.2021.39.15_suppl.1564 Get It

1564 Background: Inadequate follow-up of suspicious lung nodules can result in a delay in diagnosis and potential progression to advanced staged lung cancer. A multidisciplinary lung nodule program entitled "Nodule Net" was implemented in 2017 to provide a safety net, increase the rate of follow-up, streamline management. The program consisted of a multidisciplinary team with EMR notification by the radiologist to a centralized nurse navigator for inclusion in a follow-up database, outreach with reminders to the primary care provider if follow-up was not completed, and referral for management where appropriate. In this study, we sought to evaluate program effectiveness in tracking and rate of follow-up imaging of suspicious pulmonary nodules. Methods: 2,398 chest CT scans were reviewed between January and May 2018 for the presence of a lung nodule that required follow-up. Nodules known to be inflammatory or associated with a metastatic malignancy were excluded. Baseline demographics, medical history, primary care affiliation, type of imaging scan, nodule characteristics, and presence and specifics of follow-up recommendations were collected. For reports that did not include a follow-up recommendation, Fleischner’s recommendations were applied or an independent pulmonologist’s review was completed. The rate of follow-up imaging was recorded and compared with historical rates prior to Nodule Net implementation. Prevalence ratios were generated for each comparison. Results: 1,367 (57%) reported lung nodules. Recommendations for follow-up imaging were recorded in 632 (46.2%), and 523 (82.8%) of these were reported to the program navigator. The rate of follow-up completion of those referred to the program was significantly higher [408 (78%)] than standard of care prior to program implementation [442/1202 (36.8%), (2.90, 95% CI: 2.65-3.18)]. Out of 408 patients who completed follow-up, nodule net outreach was required in 116 (28.4%). Of these 116, malignancy was identified in 4/116 (3.4%). Increased nodule size requiring referral was identified in 17 (14.7%). Out of 109 who were not transmitted to the program navigator and not present in the database, 57 (52.3%) had completed the recommended follow-up compared with 78% among those referred (1.49, 95% CI:1.23-1.79). Conclusions: Management of lung nodules is a complex process with poor follow-up completion reported in prior studies (29%-33%). Implementation of a multidisciplinary lung nodule care program for tracking lung nodules led to a significant increase in completion of recommended follow-up imaging. Developing a comprehensive lung nodule management program using software and navigation may further enhance detection, reduce human errors, augment the necessary follow-up for suspicious lung nodules, and ultimately the prevalence of advanced stage lung cancer.
The surgical oncology clinical trial landscape: A cross-sectional analysis of ClinicalTrials.gov from 2008-2020.
Perera, Nirosha D. , Shen, Jolie , Wong, Bonnie O. , Stavins, MaKenna A. , Saleki, Massoud , Bell, Alexander , Ionescu, Ruxandra , Wang, Max , Tao, Jacqueline J. , Sarsour, Nadeen , OʼKeefe, Ryan , Takasugi, Jordan M., King, R. Michael , Turner, Brandon E. , Litt, Henry K. , Bellomo, Tiffany R. , Bell, Alexander, Ionescu, Ruxandra, Shyu, Margaret , Steinberg, Jecca R , King, Roderick, Mahipal, Amit , Wren, Sherry M

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 1561-1561

10.1200/jco.2021.39.15_suppl.1561 Get It

1561 Background: Surgical interventions are studied less often than medical or radiation interventions in oncology clinical trials. We characterized surgical oncology trials registered on ClinicalTrials.gov, analyzed funding sources and identified features associated with early discontinuation and results reporting. Methods: We employed a cross-sectional study design with descriptive, logistic regression, cox regression, time series and survival analyses. We downloaded all 270,172 studies registered on the Aggregate Analysis of the ClinicalTrials.gov database from October 1, 2008 to March 9, 2020. After excluding non-interventional trials, applying cancer/oncology specific Medical Subject Heading terms to the remaining trials and excluding phase 1 trials, 27,915 trials were identified for manual review. Primary exposure variables were trial focus: neoplasia site and treatment modality (surgical interventions included investigations of outcomes from surgical resection or intra-operative/peri-operative changes), and funding: industry, U.S. government, academic. Results: 26,815 trials were found to have true oncology content; 1,661 (6.2%) involved surgical oncology, representing 311,789 patients. Funding sources were: 82.7% by academic institutions, 10.9% by industry, and 6.2% by U.S. government. The most studied neoplasia sites were colorectal (17.4% of trials), breast (10.7%), gastric (10.5%), hepatic (8.6%), lung (7.5%), brain/CNS (6.7%) and cervical (6.6%). U.S. government funded surgical oncology trials had the lowest risk of early discontinuation (adjusted HR 0.50, 95% CI: 0.26-0.99, p<0.047) and the highest odds of results reporting (adjusted OR 1.08, 95% CI: 0.55-2.11, p=0.83) (Table 1). Conclusions: There is a paucity of surgical oncology clinical trials compared to other treatment modalities, especially in context of surgery’s role in overall cancer care. From 2008-2020 only 6.2% of trials focused on surgical oncology, and U.S. government funded trials displayed the lowest hazard of early discontinuation and highest odds of results reporting. Stakeholders should look to government funded trials as models of improvement, but must increase representation and results dissemination of surgical oncology trials to guide treatment recommendations. Surgical oncology trial features and associated early discontinuation/results reporting. [Table: see text]
ATRT-04. CORRELATION OF CLINICOPATHOLOGIC FEATURES AND CUMULATIVE INCIDENCE OF RELAPSE FOR PATIENTS WITH ATYPICAL TERATOID RHABDOID TUMOR ON ACNS0333: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
Reddy, Alyssa , Biegel, Jaclyn A. , Strother, Douglas, Judkins, Alexander R. , Pollack, Ian F. , Buxton, Allen, Mahajan, Anita , Ho, Ben, Mazewski, Claire , Lewis, Victor , Fouladi, Maryam , Krailo, Mark , Huang, Annie

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i1-i1

10.1093/neuonc/noab090.003 Get It

Abstract Purpose Intensive multi-modal regimens have improved survival for patients with atypical teratoid rhabdoid tumor, however relapse rates remain high. A better understanding of clinical and pathologic features associated with tumor relapse is critical to risk-stratifying patients. Patients and Methods ACNS0333 treatment consisted of multi-agent chemotherapy, high-dose chemotherapy, and radiation therapy, lasting approximately 6 months. Variables including patient age, sex, tumor location, M-stage, degree of resection, order of therapy, germline status, and molecular subgroup were analyzed. Cumulative incidence (CI) of event free survival due to relapse was evaluated for each variable. Results Thirty-three of 65 evaluable patients had tumor relapse. For the entire cohort, the CI of relapse was 21.8% at 6 months, 40.6% at one year and 50.3% at 4 years. For patients with infratentorial tumors, CI of relapse was 26.3%, 34.2% and 37.2%, at 6 months, 1 and 4 years respectfully compared to 15.3%, 49.9%, and 69.7% for those with supratentorial tumors (p 0.051). Patients with SHH subtype had no relapses in the first 6 months and CI of relapse of 37.5% at 4 years, while those with TYR and MYC subgroups had CI of relapse of 33.3% and 26.7% at 6 months and 46.3% and 73.3% at 4 years respectfully (p 0.088). Patients with germline mutations had a cumulative incidence of relapse of 20% at 6 months and 60% at 12 months compared to 22.6% and 37.7% respectfully for those without. No obvious trends were noted based on other analyzed variables. Conclusions ACNS0333 was not powered to determine prognostic indicators of relapse, however, this data suggest interesting trends based on tumor location, subtype and germline status. Infratentorial location and SHH subtype maybe associated with lower risk of relapse. Larger data sets must be compiled to further investigate these variables, perform multivariate analyses and inform risk-stratification on future trials.
ATRT-07. DEFINING LOST AND GAINED TRANSCRIPTIONAL REGULATORY NETWORKS IN ATYPICAL TERATOID RHABDOID TUMOR
Wixom, Alex, Nesvick, Cody L. , Zhang, Liang N. , Wixom, Alexander Q. , Hamdan, Feda H. , Johnsen, Steven A. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i2-i2

10.1093/neuonc/noab090.006 Get It

Abstract Atypical teratoid rhabdoid tumor (ATRT) is a central nervous system cancer of infancy and early childhood that may occur anywhere along the neuraxis and is associated with a high rate of mortality. While contemporary multimodal therapeutic approaches have significantly improved overall survival, targeted therapy remains elusive, and treatment is often associated with significant morbidity. ATRT is unique in its genomic stability, with the only recurrent genetic abnormality being bi-allelic loss of the SMARCB1 gene, which encodes a core subunit of the BAF chromatin remodeling complex. The epigenetic mechanisms by which SMARCB1 loss leads to tumorigenesis are not yet well-defined and addressing this gap in understanding is necessary for creating efficacious, targeted therapeutics. To better understand the epigenetic features gained and lost in ATRT, we re-expressed SMARCB1 in a library of patient-derived and established ATRT cell lines of multiple molecular subtypes. SMARCB1 restoration significantly reduced or eliminated the proliferative and clonogenic capacity of each cell line. We performed assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-Seq) and RNA sequencing (RNA-Seq) to define putative transcriptional regulatory networks that are gained and lost in ATRT. SMARCB1 restoration was associated with global changes in chromatin openness consistent with the creation of new regulatory elements throughout the genome, and these were associated with induction of a diverse developmental transcriptional signature. Motif enrichment analysis of regions with increased accessibility defined a small but consistent number of centrally enriched transcription factor motifs across cell lines indicative of putative pioneer factors whose functions may be lost in ATRT. Pertinent chromatin immunoprecipitation with sequencing (ChIP-Seq) data will be discussed in the context of lost and gained transcriptional regulatory networks in ATRT and normal cellular development.
Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study
Rost, Natalia S. , Meschia, James F. , Wruck, Lisa , Helmer, Karl G. , Greenberg, Steven M. , Investigators*, on behalf of the DISCOVERY, Barrett, Kevin M. , Biffi, Alessandro , Fornage, Myriam , Etherton, Mark R. , Golland, Polina , Graff-Radford, Jonathan, Jack, Cliff R, Kalpathy–Cramer, Jayashree , Kittner, Steven J. , Lowe, Val J. , Petersen, Ronald C. , Sherman, Alexander , Viswanathan, Anand , Meschia, James F , Wruck, Lisa M , Gottesman, Rebecca F. , Investigators*, on behalf of the DISCOVERY, Boden-Albala, Bernadette M , Graff‐Radford, Jonathan , Hinman, Jason D. , Knopman, David S. , Manly, Jennifer J. , Mosley, Thomas H. , Rissman, Robert A. , Schirmer, Markus D. , Schwab, Kristin , Seshadri, Sudha , Sherman, Alexander, Vemuri, Prashanthi

Mayo Clinic

Stroke | May 27, 2021 | Volume: 52 | Issue: 8 | Pages: No page available

10.1161/strokeaha.120.031611 | PMID 34039035 Get It

Stroke is a leading cause of the adult disability epidemic in the United States, with a major contribution from poststroke cognitive impairment and dementia (PSCID), the rates of which are disproportionally high among the health disparity populations. Despite the PSCID’s overwhelming impact on public health, a knowledge gap exists with regard to the complex interaction between the acute stroke event and highly prevalent preexisting brain pathology related to cerebrovascular and Alzheimer disease or related dementia. Understanding the factors that modulate PSCID risk in relation to index stroke event is critically important for developing personalized prognostication of PSCID, targeted interventions to prevent it, and for informing future clinical trial design. The DISCOVERY study (Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery), a collaborative network of thirty clinical performance clinical sites with access to acute stroke populations and the expertise and capacity for systematic assessment of PSCID will address this critical challenge. DISCOVERY is a prospective, multicenter, observational, nested-cohort study of 8000 nondemented ischemic and hemorrhagic stroke patients enrolled at the time of index stroke and followed for a minimum of 2 years, with serial cognitive evaluations and assessments of functional outcome, with subsets undergoing research magnetic resonance imaging and positron emission tomography and comprehensive genetic/genomic and fluid biomarker testing. The overall scientific objective of this study is to elucidate mechanisms of brain resilience and susceptibility to PSCID in diverse US populations based on complex interplay between life-course exposure to multiple vascular risk factors, preexisting burden of microvascular and neurodegenerative pathology, the effect of strategic acute stroke lesions, and the mediating effect of genomic and epigenomic variation.
Aerosol Generation During Peak Flow Testing: Clinical Implications for COVID-19
Subat, Yosuf W., Guntupalli, Siva Kamal, Sajgalik, Pavol , Hainy, Matthew E, Torgerud, Keith D, Johnson, Bruce D. , Allison, Thomas G. , Helgeson, Scott A. , Lim, Kaiser G. , Niven, Alexander S.

Mayo Clinic

Respiratory Care | May 25, 2021 | Volume: 66 | Issue: 8 | Pages: 1291-1298

10.4187/respcare.08731 | PMID 34035146 Get It

BACKGROUND: Peak flow testing is a common procedure performed in ambulatory care. There are currently no data regarding aerosol generation during this procedure. Given the ongoing debate regarding the potential for aerosol transmission of SARS-CoV-2, we aimed to quantify and characterize aerosol generation during peak flow testing. METHODS: Five healthy volunteers performed peak flow maneuvers in a particle-free laboratory space. Two devices continuously sampled the ambient air during the procedure. One device can detect ultrafine particles 0.02–1 μ m in diameter, while the second device can detect particles 0.3, 0.5, 1.0, 2.0, 5.0, and 10 μ m in diameter. Five different peak flow meters were compared to ambient baseline during masked and unmasked tidal breathing. RESULTS: Ultrafine particles (0.02–1 μ m) were generated during peak flow measurement. There was no significant difference in ultrafine particle mean concentration between peak flow meters ( P = .23): Respironics (1.25 ± 0.47 particles/mL), Philips (3.06 ± 1.22), Clement Clarke (3.55 ± 1.22 particles/mL), Respironics Low Range (3.50 ± 1.52 particles/mL), and Monaghan (3.78 ± 1.31 particles/mL). Ultrafine particle mean concentration with peak flow testing was significantly higher than masked (0.22 ± 0.29 particles/mL) and unmasked tidal breathing (0.15 ± 0.18 particles/mL, P = .01), but the ultrafine particle concentrations were small compared to ambient particle concentrations in a pulmonary function testing room (89.9 ± 8.95 particles/mL). CONCLUSIONS: In this study, aerosol generation was present during peak flow testing, but concentrations were small compared to the background particle concentration in the ambient clinical environment. Surgical masks and eye protection are likely sufficient infection control measures during peak expiratory flow testing in asymptomatic patients with well controlled respiratory symptoms, but COVID-19 testing remains prudent in patients with acute respiratory symptoms prior to evaluation and peak expiratory flow assessment while the community prevalence of SARS-CoV-2 cases remains high.
Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
Naser, Jwan A. , Petrescu, Ioana, Ionescu, Filip , Pellikka, Patricia A. , Connolly, Heidi M. , Egbe, Alexander C. , Pellikka, Patricia A , Naser, Jwan A , Nkomo, Vuyisile T. , Pislaru, Cristina , Schaff, Hartzell V. , Pislaru, Sorin V.

Mayo Clinic

Open Heart | May 24, 2021 | Volume: 8 | Issue: 1 | Pages: e001608

10.1136/openhrt-2021-001608 | PMID 34031215 Get It

Objective Bioprosthetic valve thrombosis (BPVT) is increasingly recognised as a major cause of prosthetic dysfunction in the first years postimplantation. How early abnormal gradients can be detected prior to diagnosis and how fast they normalise with anticoagulant therapy is unknown. We set forth to (1) evaluate patterns of increase in gradients prior to BPVT diagnosis and (2) characterise time-course of response to anticoagulation. Methods Patients treated with warfarin for BPVT (1999–2019) with clinically significant reduction of mean gradients (≥25%) were identified retrospectively. Recovery was defined as gradient decrease ≥50%, to postimplantation or to normal-range gradients per position, model and size. Time-to-BPVT (implantation—BPVT diagnosis), potential diagnostic delay (first abnormal gradient by position, model and size—BPVT diagnosis) and time-to-recovery (BPVT diagnosis—complete resolution) were recorded. Results 77 patients were identified; 32 (42%) aortic (23 surgical—12 porcine, 11 pericardial; 9 transcatheter); 24 (31%) mitral; 21 (27%) tricuspid. Median time-to-BPVT was 24, 21 and 10 months, respectively. Potential diagnostic delay was median 21 months for aortic, 4 months for mitral, but 0 for tricuspid. Recovery was significantly faster in mitral than aortic (median 2.5 vs 4.8 months, p=0.038) and tricuspid (median 5.9 months, p=0.025) positions. Porcine aortic valves responded faster than pericardial aortic valves (median 2.9 vs 20.3 months, p=0.004). Conclusion Gradients start to increase months before the clinical BPVT diagnosis. Recovery is faster in mitral and surgical aortic porcine valves; a longer warfarin trial seems indicated in tricuspid and surgical aortic pericardial valves.
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy
Seferović, Petar , Tsutsui, Hiroyuki , McNamara, Dennis M. , Ristić, Arsen , Basso, Cristina , Bozkurt, Biykem , Filippatos, Gerasimos , Ide, Tomomi , Inomata, Takayuki , Milinković, Ivan , Nakamura, Kazufumi , Anker, Stefan D. , Veljić, Ivana , Tschöpe, Carsten , Rosano, Giuseppe , Tschöpe, Carsten , Basso, Cristina , Cooper, Leslie T. , Klingel, Karin , Linhart, Aleš , Lyon, Alexander R. , Mehra, Mandeep R. , Polovina, Marija M. , Ohtani, Tomohito , Okumura, Takahiro , Thum, Thomas , Coats, Andrew J.S. , Starling, Randall C.

Mayo Clinic

European Journal of Heart Failure | May 19, 2021 | Volume: 23 | Issue: 6 | Pages: 854-871

10.1002/ejhf.2190 | PMID 34010472 Get It

Abstract Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumours. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples have significantly improved diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up-to-date perspective on EMB, with a focus on the following main issues: (i) an overview of the practical approach to EMB, (ii) an update on indications for EMB, (iii) a revised plan for HTx rejection surveillance, (iv) the impact of multimodality imaging on EMB, and (v) the current clinical practice in the worldwide use of EMB.
Retrospective analysis of 578 inpatient dermatology consultations in hematology and hematopoietic stem cell transplant patients
Hines, Alexander , Wetter, David A. , Bridges, Alina G. , Camilleri, Michael , McEvoy, Marian T., Davis, Mark D. P. , Sartori‐Valinotti, Julio C. , Hazim, Antonious , El-Azhary, Rokea A, Sartori-Valinotti, Julio C., Hines, Alexander S , el‐Azhary, Rokea A. , Davis, Mark D.P.

Mayo Clinic

International Journal of Dermatology | May 15, 2021 | Volume: 60 | Issue: 11 | Pages: 1385-1391

10.1111/ijd.15650 | PMID 33991106 Get It

AbstractBackgroundHospitalized patients with hematologic malignancies are medically complex and commonly affected by dermatologic conditions.MethodsRetrospective chart review from January 1, 2014, to December 31, 2018, at Rochester Methodist Hospital (Rochester, Minnesota, USA). Patients hospitalized on hematology and BMT services receiving dermatology consultation were included.ResultsIn all, 578 consultations (63% male, median age 61 years) were reviewed. Drug reactions (22%), infection (17%), and malignant neoplasm (10%) accounted for nearly half of diagnoses. Exanthematous drug reaction (10%), graft‐versus‐host disease (7%), and lymphoma or leukemia cutis (6%) were the commonest individual diagnoses. There were significantly more drug reactions in severe neutropenia (33.2% vs. 15.0%), neutrophilic dermatoses in myeloid neoplasm (5.2% vs. 0.3%), and viral infection in lymphoid neoplasm (8.3% vs. 1.2%). Consultation frequently altered treatment (68%), diagnostic workup (63%), and the primary service’s initial diagnostic impression (53%). Biopsies were performed in 52% of consultations and helped secure a diagnosis 73% of the time. A total of 16.4% of consultations did not receive a definitive final diagnosis, and 18.5% were resolved in one visit.ConclusionThis is the largest study to date of hospital dermatology consultation in hematology patients. Biopsies are utilized frequently and are diagnostically useful. The complexity of this patient population is evidenced by the fact that a final diagnosis remains elusive in a number of cases despite the multiple visits required for the vast majority of consultations. Nevertheless, dermatology consultation alters diagnosis and treatment in the majority of patients, highlighting the critical role dermatologists have in the care of these patients.